| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 21 Feb 2025 | 21 Feb 2025 |
| Pursuant to the Regulation 30 of the Listing Regulations, we hereby inform that, the Board of Directors of the Company at their Meeting held today, that commenced on February 20, 2025 at 11.00 a.m. and concluded on February 21, 2025 at 1.45 p.m have approved a proposal today, to enter into a Marketing and Supply Agreement with Mylan Pharmaceuticals Private Limited for Marketing and Sale of two brands of the Company, viz., Ativan and Pacitane | ||
| Board Meeting | 31 Jan 2025 | 24 Jan 2025 |
| PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 inter alia to consider and approve Board Meeting to consider and take on record the Unaudited Financial Results for the quarter and nine months ended December 31 2024 Outcome of the Board Meeting- Unaudited Financial Results for the quarter and nine months ended December 31, 2024 (As Per BSE Announcement Dated on: 31/01/2025) | ||
| Board Meeting | 28 Oct 2024 | 21 Oct 2024 |
| PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2024 inter alia to consider and approve Unaudited Financial Results for the quarter and half year ended September 30 2024. Outcome of the Board Meeting-Unaudited Financial Results for the quarter and half year ended September 30, 2024 (As per BSE Announcement dated on: 28/10/2024) | ||
| Board Meeting | 29 Jul 2024 | 22 Jul 2024 |
| PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2024 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter ended June 30 2024. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results for the quarter ended June 30, 2024, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 4.00 p.m. and concluded at 7.25 p.m. Also please find enclosed the Limited Review Report by our Statutory Auditors, M/s. B. S. R. & Co., LLP, in respect of the said results Intimation pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure) Regulations, 2015. (As per BSE Announcement Dated on 29/07/2024) | ||
| Board Meeting | 17 May 2024 | 6 May 2024 |
| PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve the Audited Financial Results of the Company for the Financial Year ended March 31 2024 and to consider recommendation of dividend if any for the Financial Year ended March 31 2024. The Board of Directors has at its Meeting held today, i.e., May 17, 2024, recommended a dividend of Rs. 35/- per equity share of Rs. 10/- each (350%) for the financial year ended March 31, 2024. The said dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 6, 2024. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Audited financial results for the financial year ended March 31, 2024, Statement of Assets and Liabilities as on March 31, 2024, Statement of Audited Cash Flows for the year ended March 31, 2024, Declaration with respect to Audit Report with unmodified opinion and the Auditors Report by our Statutory Auditors, M/s. B S R & Co., LLP. The Audited financial results for the year ended March 31, 2024 were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 3:00 p.m. and concluded at 7:15 p.m (As Per NSE Announcement Dated on 17.05.2024) We refer to our letter dated May 17, 2024, informing you about the Audited Financial Results for the financial year ended March 31, 2024, Statement of Assets and Liabilities as on March 31, 2024, Statement of Audited Cash Flows for the year ended March 31, 2024 and Declaration with respect to unmodified opinion. We wish to bring to your notice that by oversight the Auditors Report was not attached with the said filing. Please find attached Auditors Report dated May 17, 2024, by our Statutory Auditors, M/s. B.S.R. & Co. LLP. Please note that there are no changes in the Audited Financial Results for the year ended March 31, 2024, published on May 17, 2024. Request you to please take the above on record. Read less.. (As Per BSE Announcement Dated on 27.05.2024) | ||
Ativan is a common medication used predominantly for anxiety disorders, whereas Pacitane is used for Parkinson’s disease and other neurological conditions.
The agreement, which is discussed up to April and approved by Pfizer's Board of Directors, will be for five years, with discussions ending on 21 February 2025.
Revenue from operations decline marginally by 0.4% YoY at ₹538 crore, as against ₹540 crore in Q3 FY24
At the operating level, EBITDA increased by 60.2%, reaching ₹177.5 Crore in the first quarter of this fiscal year, compared to ₹110.8 Crore in the same quarter last year.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
